Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 532

1.

Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2012 Aug;110(4):492-8. doi: 10.1111/j.1464-410X.2011.10754.x. Epub 2011 Nov 17.

PMID:
22094083
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
[PubMed - indexed for MEDLINE]
3.

Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

Eur Urol. 2014 Mar;65(3):620-7. doi: 10.1016/j.eururo.2012.11.052. Epub 2012 Dec 6.

PMID:
23245686
[PubMed - indexed for MEDLINE]
4.

Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.

Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ.

BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x. Epub 2008 Aug 7.

PMID:
18691175
[PubMed - indexed for MEDLINE]
5.

Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.

Baade PD, Youlden DR, Gardiner RA, Ferguson M, Aitken JF, Yaxley J, Chambers SK.

BJU Int. 2012 Dec;110(11 Pt B):E712-9. doi: 10.1111/j.1464-410X.2012.011533.x. Epub 2012 Sep 27.

PMID:
23017157
[PubMed - indexed for MEDLINE]
6.

Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database.

Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

Eur Urol. 2012 Nov;62(5):910-6. doi: 10.1016/j.eururo.2012.08.015. Epub 2012 Aug 20.

PMID:
22921964
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.

Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ.

Cancer. 2014 Jan 15;120(2):197-204. doi: 10.1002/cncr.28423. Epub 2013 Oct 11.

PMID:
24127391
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.

Song C, Kim YS, Hong JH, Kim CS, Ahn H.

BJU Int. 2010 Jul;106(2):188-93. doi: 10.1111/j.1464-410X.2009.09136.x. Epub 2009 Dec 11.

PMID:
20002666
[PubMed - indexed for MEDLINE]
9.

The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.

Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC, Trock BJ.

J Urol. 2008 Jan;179(1):156-61; discussion 161-2. Epub 2007 Nov 14.

PMID:
18001801
[PubMed - indexed for MEDLINE]
10.

Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study.

Lycken M, Garmo H, Adolfsson J, Stattin P, Holmberg L, Bill-Axelson A.

Eur J Cancer. 2014 Jul;50(10):1789-98. doi: 10.1016/j.ejca.2014.03.279. Epub 2014 Apr 12.

PMID:
24736041
[PubMed - indexed for MEDLINE]
11.

Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.

Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG.

J Clin Oncol. 2004 Feb 1;22(3):439-45. Epub 2003 Dec 22.

PMID:
14691120
[PubMed - indexed for MEDLINE]
Free Article
12.

Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database.

Wu C, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2013 Jun;111(8):E310-8. doi: 10.1111/j.1464-410X.2012.11687.x. Epub 2013 Jan 10.

PMID:
23305170
[PubMed - indexed for MEDLINE]
13.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
[PubMed - indexed for MEDLINE]
14.

20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.

Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ.

BJU Int. 2012 Dec;110(11):1709-13. doi: 10.1111/j.1464-410X.2012.11372.x. Epub 2012 Aug 30.

PMID:
22934913
[PubMed - indexed for MEDLINE]
15.

Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.

Palma D, Tyldesley S, Pickles T; Prostate Cohort Outcomes Initiative.

Cancer. 2008 May 1;112(9):1941-8. doi: 10.1002/cncr.23388.

PMID:
18338814
[PubMed - indexed for MEDLINE]
Free Article
16.
17.

Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.

Palma D, Pickles T, Tyldesley S; Prostate Cohort Outcomes Initiative.

BJU Int. 2007 Aug;100(2):315-9.

PMID:
17617138
[PubMed - indexed for MEDLINE]
18.

Impact of body mass index on clinicopathological outcome and biochemical recurrence after radical prostatectomy.

Narita S, Mitsuzuka K, Yoneyama T, Tsuchiya N, Koie T, Kakoi N, Kawamura S, Kaiho Y, Ohyama C, Tochigi T, Yamaguchi T, Habuchi T, Arai Y.

Prostate Cancer Prostatic Dis. 2013 Sep;16(3):271-6. doi: 10.1038/pcan.2013.16. Epub 2013 Jun 11.

PMID:
23752230
[PubMed - indexed for MEDLINE]
19.

The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer.

Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.

Cancer. 2014 Jun 1;120(11):1656-62. doi: 10.1002/cncr.28647. Epub 2014 Mar 19.

PMID:
24647966
[PubMed - indexed for MEDLINE]
20.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk